187 related articles for article (PubMed ID: 22502587)
1. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis.
Gupta R; Kushawaha PK; Tripathi CD; Sundar S; Dube A
Int J Parasitol; 2012 May; 42(5):429-35. PubMed ID: 22502587
[TBL] [Abstract][Full Text] [Related]
2. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
3. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
4. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
[TBL] [Abstract][Full Text] [Related]
5. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
[TBL] [Abstract][Full Text] [Related]
6. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
[TBL] [Abstract][Full Text] [Related]
7. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
[TBL] [Abstract][Full Text] [Related]
8. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.
Khare P; Jaiswal AK; Tripathi CD; Joshi S; Sundar S; Dube A
Parasitol Res; 2014 Mar; 113(3):851-62. PubMed ID: 24370734
[TBL] [Abstract][Full Text] [Related]
10. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
11. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
[TBL] [Abstract][Full Text] [Related]
12. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
15. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.
Garg R; Gupta SK; Tripathi P; Naik S; Sundar S; Dube A
Clin Exp Immunol; 2005 Apr; 140(1):149-56. PubMed ID: 15762886
[TBL] [Abstract][Full Text] [Related]
17. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
18. Immunological consequences of stress-related proteins--cytosolic tryparedoxin peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis.
Jaiswal AK; Khare P; Joshi S; Rawat K; Yadav N; Sundar S; Dube A
Parasitology; 2015 Apr; 142(5):728-44. PubMed ID: 25498563
[TBL] [Abstract][Full Text] [Related]
19. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model.
Anand A; Balodi DC; Ramalingam K; Yadav S; Goyal N
Mol Immunol; 2022 Jan; 141():33-42. PubMed ID: 34798496
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
